In November 2017, Merck reported slight reduction of β-amyloid burden below baseline by 2–4% after 18 months long treatment of mild-to-moderate AD patients with the BACE1 inhibitor verubecestat (Clinical Trials on Alzheimer’s Disease conference). This evidence concerns the gene BACE1 and Alzheimer disease.